Celyad Oncology SA
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Regulatory News:
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on July 30, 2021, a capital increase of 300,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 54,956,224.33 EUR and is represented by 15,793,956 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on 30 July 2021 following the Capital Increase:
Total amount of share capital (EUR) |
54,956,224.33 |
Total Number of shares with single voting rights |
13,425,931 |
Total Number of shares with double voting rights |
2,368,025 |
Total Number of Shares |
15,793,956 |
Total of voting rights |
18,161,981 |
Total number of attributed warrants |
1,922,423 |
Total number of shares with voting rights that could be created following the exercise of the attributed warrants |
1,922,423 |
Total number of diluted shares (Outstanding shares + Warrants) |
17,716,379 |
Total number of diluted shares with voting rights |
20,084,404 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
Lesen Sie auch
About Celyad Oncology
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.